Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP8 | P22894 | 1/20 | 0.49 |
| ▸ | MMP12 | P39900 | 1/20 | 0.49 |
| ▸ | MMP13 | P45452 | 1/20 | 0.49 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.48 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.48 |
| ▸ | ACLY | P53396 | 7/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | WDR5 | P61964 | 6/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4609587 | 1.00 | MMP8 (0.49) | MMP8MMP12MMP13HCRTR1HCRTR2 | |
| SCHEMBL4611418 | 0.87 | ACLY (0.62) | MMP8MMP12MMP13ACLYALDH1A1 | |
| SCHEMBL4610455 | 0.87 | MMP8 (0.45) | MMP8MMP12MMP13HCRTR1HCRTR2 | |
| SCHEMBL4611376 | 0.87 | MMP8 (0.45) | MMP8MMP12MMP13HCRTR1HCRTR2 | |
| SCHEMBL4610371 | 0.87 | ACLY (0.62) | MMP8MMP12MMP13ACLYALDH1A1 | |
| SCHEMBL4611645 | 0.85 | MMP8 (0.49) | MMP8MMP12MMP13HCRTR1HCRTR2 | |
| SCHEMBL4610646 | 0.84 | ACLY (0.67) | MMP8MMP12MMP13ACLYALDH1A1 | |
| SCHEMBL4610642 | 0.84 | ACLY (0.67) | MMP8MMP12MMP13ACLYALDH1A1 | |
| SCHEMBL4612655 | 0.84 | ACLY (0.67) | MMP8MMP12MMP13ACLYALDH1A1 | |
| SCHEMBL4611514 | 0.82 | MMP8 (0.49) | MMP8MMP12MMP13ACLYALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070225344-A1 | Sulfonamide derivatives to treat infection with hepatitis C virus | WYETH | 2007-09-27 | — | — | US | claimed |
| US-20070225344-A1 | Sulfonamide derivatives to treat infection with hepatitis C virus | WYETH | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225344-A1 | Sulfonamide derivatives to treat infection with hepatitis C virus | HCCS, HAVCR2, SULT2A1 | MMP8 3676/4885MMP12 2873/4885MMP13 3847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.